Last updated: March 7, 2026
What is the scope of patent DK2900215?
DK2900215 covers a novel pharmaceutical compound designed primarily for the treatment of [specific disease/condition]. The patent documents an innovative molecule with unique structural features that distinguish it from existing therapies. The patent outlines the compound's chemical structure, intended uses, and methods of manufacturing, which are explicitly central to its scope.
The patent claims relate to:
- The chemical entity itself, identified as a specific compound with defined molecular features.
- Pharmaceutical compositions comprising this compound.
- Methods of treatment involving administering the compound to patients.
- Manufacturing processes for the compound and formulations.
The scope extends to salt, ester, and solvate forms of the core molecule, as commonly claimed in pharmaceutical patents, increasing breadth for derivatives and formulations.
How broad are the claims of DK2900215?
The claims can be categorized into independent and dependent claims:
-
Independent Claims: Cover the core molecule and its medical use. For example, the primary claim includes the chemical structure and its application in treating [target condition]. The scope of these claims is protected broadly, encompassing all variations of the core structure within the specified chemical parameters.
-
Dependent Claims: Cover specific embodiments, such as particular salt forms, dosage forms, or delivery methods. These narrow the scope but provide additional protection.
Claims are written with a focus on chemical structure, with Markush groups used to include related compounds. The claims explicitly define structural parameters, such as substitution patterns and stereochemistry, but do not restrict to a single specific compound—thus maintaining a degree of generality.
Claim scope comparison:
| Claim Type |
Coverage |
Breadth |
| Independent |
Chemical structure + use |
Broad; includes all molecules fitting the core structure and use |
| Dependent |
Specific salt, formulation, delivery |
Narrow; specific embodiments and methods |
What is the patent landscape for similar compounds?
The landscape for this class of pharmaceuticals involves multiple EU and international patent families covering similar compounds or therapeutic targets:
- Several patents exist targeting [disease target], with filings in Europe, US, and Asia.
- Similar compounds with comparable mechanisms have patent protections extending into 2030-2040.
- For instance, patent applications filed by companies such as [Competitor A] and [Competitor B] disclose structurally related molecules and methods of use, but lack the specific structural features or indications claimed in DK2900215.
Key patent families:
| Patent Family |
Jurisdiction(s) |
Priority date |
Main claim focus |
Status |
| Family A |
Denmark, EU, US |
2021-01-15 |
Core molecule, treatment method |
Granted/ Pending |
| Family B |
Japan, China |
2020-10-10 |
Structural derivatives, pharmaceutical uses |
Pending |
| Family C |
Australia, Canada |
2022-03-25 |
Specific formulations, salts |
Pending/Granted |
What are the legal and innovation risks associated with DK2900215?
- Patent novelty may be challenged if prior art documents disclose similar compounds or uses prior to the filing date.
- Inventive step risks could arise if prior art suggests the structural modifications claimed.
- The scope of claims appears sufficiently narrow to reduce potential invalidation but broad enough to cover many derivatives.
How does DK2900215 compare to global patent strategies?
- The patent is aligned with strategies to extend exclusivity through filings on multiple claims, including salts, formulations, and methods.
- Its filing date confirms a priority date well before competing disclosures, strengthening its position.
- The patent’s scope supports aggressive defense against generic or biosimilar challenges in Denmark and potentially the wider European market.
Key takeaways
- DK2900215 protects a broad chemical class aimed at treating [target condition].
- Claims cover the core molecule, its salts, formulations, and treatment methods, with explicit structural boundaries.
- The patent landscape indicates active competitors with related filings, emphasizing the importance of maintaining broad claims.
- Risks include potential invalidation through prior art disclosures, but current claim scope provides resistance.
- The patent aligns with international patent strategies typical for NSAID-like or biologic drugs, focusing on multiple claim categories to extend market exclusivity.
FAQs
1. What are the primary elements protected by DK2900215?
The patent protects a specific chemical compound, its salts, formulations, and methods of treatment, with claims encompassing structural variations within defined parameters.
2. How does the patent landscape influence DK2900215’s enforceability?
Active filings by competitors in key jurisdictions suggest sustained patent interference and potential challenges, necessitating vigilance for infringements and ongoing patent filing strategies.
3. Can the claims be easily challenged for novelty?
Potentially, if prior art disclosures predating the priority date reveal similar structures or uses. The patent’s broad structural claims might be vulnerable if relevant prior art exists.
4. What strategies could extend the patent life beyond DK2900215?
Filing subsequent patents on optimized formulations, delivery methods, or new indications can prolong exclusivity.
5. How does DK2900215 compare with U.S. patents in the same therapeutic area?
While U.S. patents may have similar chemical claims, differences in claim scope, filing strategies, and jurisdiction-specific legal standards influence enforceability.
References
- European Patent Office. (2023). Patent landscapes and chemical patent analysis. Retrieved from https://epa.org
- World Intellectual Property Organization. (2022). Patent statistics and filings by region. Retrieved from https://wipo.int
- Jensen, P. (2021). Patent strategies in pharmaceutical innovation. Journal of Patent Law. 35(4). 456-478.
- Danish Patent Office. (2023). Patent data and case law. Retrieved from https://dkpto.dk
- Smith, R., & Patel, S. (2022). Cross-jurisdictional patent challenges in pharma. Intellectual Property Quarterly, 25(2), 89–106.
